This bill aims to stop “double patenting” on medicines so cheaper generics and biosimilars can reach patients sooner. If a drug company lists more than one patent for the same drug, it must prove in certain court or FDA‑related challenges that each patent covers a truly different invention. If it can’t, protection from the extra patents ends when the first patent runs out, rather than stretching exclusivity longer through overlapping patents .

It also tells the U.S. Patent and Trademark Office to review how it examines drug and biologic patents, make improvements to avoid granting multiple patents on the same product unless they are distinct inventions, and report recommendations to Congress within one year of the law taking effect .

Key points

• Who is affected: Brand‑name drug makers, generic and biosimilar manufacturers, and patients and health plans that pay for medicines.
• What changes: In certain patent disputes, patent owners must prove each listed patent is for a different invention or lose added protection after the first patent expires; USPTO must review and improve its examination process for these patents .
• When: The USPTO report is due within one year after enactment; the new rules apply in the specified patent challenges and lawsuits once the law is in effect.